Trend towards high-dose, once-daily mesalazine for ulcerative colitis
Clinical trials and hospitals are beginning to use higher doses of mesalazine for ulcerative colitis, according to Anja St. Clair Jones, lead pharmacist, surgery and digestive disease at Brighton and Sussex University Hospitals NHS Trust.
In a prescribing and medicines management article, she writes that although the European Crohn’s and Colitis Organisation recommends a minimum daily dose of 1g to maintain remission, evidence is emerging that daily doses of 2g and above may be more effective.
Moreover, non-adherence in patients in remission can be a big problem, with considerable clinical impact. One study, for example, found that adherence to therapy reduces the risk of colorectal cancer by 75 per cent. Mrs St. Clair Jones argues that, bearing in mind the importance of adherence, cheaper preparations that mean a high tablet burden or large tablets may not be the best option.
Citation: The Pharmaceutical Journal URI: 11021798
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com